Cadrenal CEO Pham Quang X Trims Shares in Steady Insider Sell‑off Amid Stock’s 71% YTD Decline

Insider Selling Hot‑Spot at Cadrenal Therapeutics The latest 4‑form filing on June 16, 2026 shows Chairman, CEO and Interim CFO Pham Quang X selling 3,613 shares at an average price of $3.18 under a Rule 10b‑5‑1 trading plan. This sale is part of a broader pattern of daily trades over the last month, with the owner liquidating between 1,400 and 14,900 shares in each transaction and prices ranging from $3.04 to $4.42. The most recent sale occurs at a market price of $3.10, a 13.15 % week‑down from the previous close and only marginally above the 52‑week low of $3.02.

What This Means for Investors The frequency and size of Pham’s trades signal a sustained disposition strategy rather than a single opportunistic sale. The fact that the trades are executed under a pre‑arranged Rule 10b‑5‑1 plan mitigates concerns of insider misuse but does raise questions about confidence in the company’s near‑term prospects. Investors may interpret the pattern as an indicator that key management is gradually monetizing personal holdings in anticipation of a liquidity event, a shift in corporate strategy, or a response to the company’s steep quarterly performance declines (a 71.66 % YTD drop). The recent 10.81 % social media buzz coupled with a neutral sentiment score suggests that the market reaction is muted, but the sustained selling pressure could amplify downward pressure on the stock price if the broader investor base follows suit.

Pham Quang X: A Profile of Trading Behavior Across the past 18 months, Pham has sold roughly 600,000 shares, reducing his stake from 200,000 to 129,102 shares by mid‑June 2026. His trade volumes have trended downward over the past week, from 14,900 shares on June 10 to 1,400 shares on June 16, reflecting a possible shift to smaller, more frequent sales. Historically, the owner’s transactions have been executed at prices close to the market level, suggesting a passive selling strategy rather than aggressive price‑targeted liquidations. The presence of a substantial holding block (200,000 shares) indicates that Pham still retains significant exposure to Cadrenal’s long‑term upside, yet the incremental sales may signal a tactical rebalancing of his portfolio.

Strategic Outlook for Cadrenal Cadrenal’s core pipeline, tecarfarin for ESRD patients with atrial fibrillation, remains in the development stage with limited commercial traction. The company’s market cap of just $8.7 million and negative price/earnings ratio of –0.598 reflect a high valuation risk profile. The current insider selling activity, coupled with the company’s steep YTD decline, could erode investor confidence unless offset by clear milestones—such as a phase‑II study completion or a regulatory filing. For the short term, the stock will likely remain volatile and sensitive to any announcement that either confirms or undermines the company’s therapeutic roadmap.

Bottom Line Pham Quang X’s recent sell orders are part of a consistent, low‑price, Rule 10b‑5‑1 trading pattern that aligns with broader insider liquidation trends in the company. While the sales themselves are compliant and not necessarily indicative of bad news, the cumulative effect of continuous selling could exert downward pressure on Cadrenal’s already weak stock price. Investors should monitor the company’s clinical developments and any changes in insider holdings closely, as these factors will likely dominate the narrative in the coming months.